Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

José Luis Ordóñez; Ana Teresa Amaral; Angel M. Carcaboso; David Herrero-Martín; María del Carmen García-Macías; Vicky Sevillano; Diego Alonso; Guillem Pascual-Pasto; Laura San-Segundo; Monica Vila-Ubach; Telmo Rodrigues; Susana Fraile; Cristina Teodosio; Agustín Mayo-Iscar; Miguel Aracil; Carlos María Galmarini; Oscar M. Tirado; Jaume Mora; Enrique de Álava

doi:10.18632/oncotarget.18610

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

José Luis Ordóñez _, Ana Teresa Amaral, Angel M. Carcaboso, David Herrero-Martín, María del Carmen García-Macías, Vicky Sevillano, Diego Alonso, Guillem Pascual-Pasto, Laura San-Segundo, Monica Vila-Ubach, Telmo Rodrigues, Susana Fraile, Cristina Teodosio, Agustín Mayo-Iscar, Miguel Aracil, Carlos María Galmarini, Oscar M. Tirado, Jaume Mora and Enrique de Álava

PDF | How to cite

Oncotarget. 2017; 8:43592-43592. https://doi.org/10.18632/oncotarget.18610

Metrics: PDF 1915 views | ?

Present: The published funding information is incomplete.

Corrected: Additional funding information is given below.

FUNDING

This work was supported by Menarini Spain, grants PI 15/00598 from Fondo de Investigaciones Sanitarias (FIS) Carlos III Institute to A.A .; SAF2013-47611R from The Ministry of Economy and Competitiveness and grant S2010 / BMD-2321 (FIBROTEAM Consortium) from Autonomous Community of Madrid to M.L.-C .; G.L. Was Fully supported from theEuropean ETRiPD Marie Curie Project.

Original article: Oncotarget. 2015; 6:18875-90. DOI:10.18632/oncotarget.4303.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18610

Publication Alerts

Corrections:

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin